Valuation: Insmed Incorporated

Capitalization 3.02TCr 2.6TCr 2.35TCr 2.26TCr 4.11TCr 2,77600Cr 4.3TCr 28TCr 11TCr 1,33100Cr 11TCr 11TCr 4,76100Cr P/E ratio 2026 *
-52.1x
P/E ratio 2027 * 172x
Enterprise value 2.95TCr 2.54TCr 2.3TCr 2.2TCr 4.02TCr 2,71000Cr 4.2TCr 27TCr 11TCr 1,30000Cr 11TCr 11TCr 4,64800Cr EV / Sales 2026 *
17.5x
EV / Sales 2027 * 10.8x
Free-Float
98.99%
Yield 2026 *
-
Yield 2027 * -
1 day-2.40%
1 week-6.16%
Current month-6.16%
1 month-6.49%
3 months-31.31%
6 months-3.43%
Current year-19.48%
1 week 139.89
Extreme 139.89
150.27
1 month 139.89
Extreme 139.89
167.37
Current year 139.89
Extreme 139.89
186.19
1 year 60.4
Extreme 60.4
212.75
3 years 16.04
Extreme 16.04
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 9.02
Extreme 9.02
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Director of Finance/CFO 45 31/01/2020
Chief Tech/Sci/R&D Officer 62 19/12/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 71 30/10/2013
Change 5d. change 1-year change 3-years change Capi.($)
-2.40%-6.16%+87.11%+608.08% 3.02TCr
-0.61%-5.35%+12.03%+92.93% 4.42TCr
+0.92%-4.81%+49.26%+14.90% 4.05TCr
-0.44%-7.92%-6.69%-21.33% 2.55TCr
+2.54%-9.65%+53.01%-34.70% 1.92TCr
-2.62%-6.49%+4.16%-31.60% 1.65TCr
+5.20%+0.37%+47.19%+154.57% 1.26TCr
+1.14%-8.92%-15.02%+994.93% 1.17TCr
+4.43%-0.31%+55.98% - 1.15TCr
+0.64%-5.71%+7.69%+152.09% 1.08TCr
Average +0.88%-5.14%+29.47%+214.43% 2.23TCr
Weighted average by Cap. +0.31%-5.19%+32.43%+173.27%

Financials

2026 *2027 *
Net sales 168.12Cr 144.95Cr 130.85Cr 125.55Cr 228.95Cr 15TCr 239.61Cr 1.55TCr 619.71Cr 7.41TCr 630.98Cr 617.53Cr 26TCr 272.46Cr 234.91Cr 212.06Cr 203.47Cr 371.04Cr 25TCr 388.31Cr 2.51TCr 1TCr 12TCr 1.02TCr 1TCr 43TCr
Net income -57Cr -49Cr -45Cr -43Cr -78Cr -5.27TCr -82Cr -527.39Cr -211.28Cr -2.53TCr -215.12Cr -210.54Cr -9.03TCr 17Cr 15Cr 13Cr 13Cr 23Cr 1.57TCr 24Cr 157.22Cr 63Cr 753.04Cr 64Cr 63Cr 2.69TCr
Net Debt -71Cr -62Cr -56Cr -53Cr -97Cr -6.57TCr -101.83Cr -657.42Cr -263.38Cr -3.15TCr -268.17Cr -262.45Cr -11TCr -80Cr -69Cr -62Cr -59Cr -108.43Cr -7.32TCr -113.47Cr -732.57Cr -293.48Cr -3.51TCr -298.82Cr -292.45Cr -13TCr
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
Employees
1,664
Date Price Change Volume
06/26/06 140.13 $ -2.40% 24,87,053
05/26/05 143.57 $ -4.21% 22,69,846
04/26/04 149.88 $ +1.96% 20,16,270
03/26/03 147.00 $ +0.46% 19,37,852
02/26/02 146.32 $ -2.02% 26,70,172
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
140.13USD
Average target price
212.53USD
Spread / Average Target
+51.66%

Quarterly revenue - Rate of surprise